foreign exchange gain (loss) has taken into account fair value valuation of derivatives in accordance with TFRS9. 3. Adjusted Net Income is net profit attributed to the Company excluding "fair value of
(39.66) (6.45) Costs and Expenses 554.34 579.71 (25.37) (4.38) Profit (Loss) -Net 18.11 30.02 (11.91) (39.67) Income of Sale and Administration Transaction For the Year ended 31st December (Unit: Million
the U.K. 3) Other revenue of THB 103.4mn, which grew by THB 81.5mn or 372.5% when compared to the same period last year. The increase was primarily due to a gain of THB 70.3mn from the 50% divestment of
million in net profit, increasing Baht 151 million or 1.40 percent over-quarter. The increase came from net interest income, which rose Baht 671 million, or 2.83 percent. Net interest margin (NIM) was equal
% 51.4% 58.9% Remark: * EBITDA = Earnings before Interest, Taxes, Depreciation and Amortization - Non-operating income / (expense) ** Normalized net profit = Net profit – Unrealized gain / (loss) from FX
of goods 3,276 3,278 (0%) Gain from the creditor reduce the debts 2 - 100% Net foreign exchange gains 50 16 220% Gain for debt restructuring - 7 (100%) Other income 13 10 32% Total income 3,341 3,311 1
voluntary tender offer for the entire securities of PB. (5) Purpose of transaction : To reduce its investment proportion in non-core business, as well as to receive capital gain on the sale of shares. (6
% 7.69% Even though the total revenue decreased compared to the previous year, the net profit margins are improving as a result of the gain from foreign exchange in the 3-month period ended 31 March 2020
with the same period of last year. The income statement in brief is presented as following: DOD BIOTECH PUBLIC COMPANY LIMITED เลขที ่111 หมู่ที ่2 ต ำบลท่ำจีน อ ำเภอเมืองสมุทรสำคร จังหวดัสมุทรสำคร 74000
totaled Baht 9,929 million, decreasing Baht 115 million or 1.15 percent from the previous quarter. KBank still recorded increased income. As evidenced, both net interest income and non- interest income rose